EP0433084A2 — Use of aromatese inhibitors for the reversal of female sexual phenotype in poultry
Assigned to Merck and Co Inc · Expires 1991-06-19 · 35y expired
What this patent protects
Fertilized poultry embryos are treated with steroid biosynthesis inhibitors or antagonists which prevents the conversion of androgens to estrogens. By blocking the production of estrogens the genotypic female is converted into a phenotypic male. The phenotypic conversion of femal…
USPTO Abstract
Fertilized poultry embryos are treated with steroid biosynthesis inhibitors or antagonists which prevents the conversion of androgens to estrogens. By blocking the production of estrogens the genotypic female is converted into a phenotypic male. The phenotypic conversion of females to males gives the treated birds the advantage of male growth characteristics. A single administration of a steroid biosynthesis inhibitor or antagonist prior to about day 9 of embryonic incubation results in an irreversible change the sexual phenotype. <IMAGE>
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.